The Phase II Urokinase-Streptokinase Pulmonary Embolism Trial^[*]

Summary

The controlled clinical trials of thrombolytic agents in the United States have been carried out in two phases, under the auspices of the National Heart and Lung Institute. Phase I was devoted to the comparison of 12-hour Urokinase (12h–UK) followed by heparin (H) with heparin alone in patients with acute pulmonary embolism (Walsh et al. 1969). The results showed that patients treated with UK had more rapid and greater resolution of pulmonary thromboemboli in the first twenty-four hours of therapy than patients treated with H alone, as assessed by serial pulmonary angiography, hemodynamics and lung scanning (The Urokinase Pulmonary Embolism Trial, 1970, 1973 ; Hyers et al. 1970). Because of the relatively small size of the Trial and the low mortality of treated pulmonary embolism, mortality differences were not sought - nor was one found. Although there was early difference in amount of clot resolution, patients treated with H alone showed similar improvement by two weeks.

The Phase II Urokinase-Streptokinase Pulmonary Embolism Trial (USPET) was begun to assess the comparative results of UK and Streptokinase (SK) therapy. Because of favorable results obtained with SK in other countries, it was deemed necessary to make this comparison (Browse and James, 1964 ; Hirsh et al. 1968 ; Miller et al. 1969, 1971 ; Chesterman et al. 1969). A third group, 12-hour UK, was added to relate this study (24-hour UK and SK) with the Phase I results which employed only a 12-hour infusion of UK. This Phase II Trial represents the first controlled, randomized study of UK and SK in thromboembolic disorders.

^* Presented at the National Conference on Thrombosis and Hemostasis, under the auspices of the Council on Thrombosis of the American Heart Association, Dallas, Texas, November 1974.

• References

• 1 Armitage P. Statistical Methods in Medical Research . New York: John Wiley and Sons, Inc; 1971: 387
• 2 Armitage P, McPherson O.K, Rowe B.C. Repeated significance tests on aceumulatin data. Journal of the Royal Statistical Society Series A 1969; 235: 132
• 3 Browse N. L, James D. C. O. Streptokinase and pulmonary embolism. Lancet 1964; 2: 1039
• 4 Chesterman C. N, Biggs J. C, Morgan J, Hickie J. B. Streptokinase therapy in acute major pulmonary embolism. Medical Journal of Australia 2 1969; 1096
• 5 Genton E. Fibrinolytic treatment of pulmonary thromboembolism. To be submitted for publication. 1975
• 6 Hirsh J, Hale G. I, McDonald I. G. Streptokinase therapy an acute major pulmonary embolism: Effectiveness and problems. British Medical Journal 1968; 4: 729
• 7 Hyers T. H, Stengle J. M, Sherry S. Treatment of pulmonary embolism with urokinase: Results of a clinical trial (Phase I). Circulation 1970; 42: 979
• 8 Miller G. A. H, Gibson R. V, Hanley M. et al. Treatment of pulmonary embolism with streptokinase. A preliminary report. British Medical Journal 1969; 1: 812
• 9 Miller G. A. H, Sutton G. C, Kerr I. H. et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. British Medical Journal 1971; 2: 681
• 10 Sautter R. D, Myers W. O, Wenzel F. J. Implications of the urokinase study concerning the surgical treatment of pulmonary embolism. Journal of Thoracic and Cardiovascular Surgery 1972; 63: 54
• 11 Sherry S. Current Status of urokinase therapy. In Moser K, Stein M. (eds.) Pulmonary Thromboembolism . Chicago: Yearbook Medical Publishers; 280 1973
• 12 Urokinase Pulmonary Embolism Trial. Journal of the American Medical Association 1970; 214: 2163
• 13 Urokinase Pulmonary Embolism Trial. Circulation 1973; 47 Supplement ll 1
• 14 Walsh P. N, Stengle J. M, Sherry S. The Urokinase Pulmonary Embolism Trial. Circulation 39 1969; 153
• 15 Walsh P. N, Greenspan M, Simon M. et al. An angiographic severity index for pulmonary embolism. Circulation 1973; 47 Supplement ll 101